Impact of Mirikizumab Maintenance Dosing at Week 104 on Health-related Quality of Life in Patients Who Had < PASI90 Response at Week 16: A Phase 2 Study Analysis
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Mirikizumab is a monoclonal antibody that binds to the p19-subunit of IL-23
- This study aimed to determine whether mirikizumab maintenance dosing improves HRQoL as measured by the Dermatology Life Quality Index and the Medical Outcomes Study 36-Item Short-Form Health Survey in patients who had
- Patients who had not obtained PASI90 at Week 16 on mirikizumab continued to have improved DLQI and SF-36 with 300 mg q8wk dosing through Week 104
- These findings support the long-term efficacy of mirikizumab 300 mg Q8W dosing in moderate-to-severe plaque psoriasis
Presenting Author
Jerry Bagel, MD, MS
Psoriasis Treatment Center of New Jersey
Clinical Professor of Dermatology: Mt Sinai School of Medicine
Clinical Associate Professor of Dermatology: University of Pisa
Board of Director: National Psoriasis Foundation
Medical Advisory Board: Four-term member: Medical Advisory Board: National Psoriasis Foundation
Author disclosures
Jerry Bagel has served as a speaker, advisor, or investigator for: AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen, Leo Pharma, and Novartis.